Clinical Report: Does Timing Matter in Gene Therapy for nAMD?
Overview
The 2-year phase 2b PRISM results indicate that investigational gene therapy 4D-150 shows durable outcomes in patients with recently diagnosed neovascular age-related macular degeneration (nAMD). Notably, 66% of patients required no additional injections over two years, and 87% had significantly fewer injections compared to standard care.
Background
Neovascular age-related macular degeneration (nAMD) poses a significant threat to vision, often requiring frequent injections of anti-VEGF therapies. The burden of treatment can lead to undertreatment, impacting patient outcomes. Innovative therapies like gene therapy aim to reduce injection frequency while maintaining effective vision preservation.
Data Highlights
Outcome
Percentage
Patients with no additional injections over 2 years
66%
Patients with 2 or fewer injections over 2 years
87%
Key Findings
66% of patients went 2 years without additional injections.
87% had fewer injections than standard-of-care aflibercept.
Most patients maintained vision with great optical coherence tomography (OCT) outcomes.
Only 2 eyes experienced minimal iritis, treated with topical therapy.
No serious adverse events reported over 4 years of follow-up.
Clinical Implications
The safety profile observed in the study supports further exploration of gene therapies in clinical practice.
Conclusion
Continued research is anticipated to further validate these findings in larger trials.
